Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development

Mertens, JE; Rigby, CA; Bardelli, M; Quinkert, D; Hou, MM; Diouf, A; Silk, SE; Chitnis, CE; Minassian, AM; Moon, RW; Long, CA; Draper, SJ; Miura, K

Journal article

Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development

Abstract:: Recent data indicate increasing disease burden and importance of Plasmodium vivax (Pv) malaria. A robust assay will be essential for blood-stage Pv vaccine development. Results of the in vitro growth inhibition assay (GIA) with transgenic P. knowlesi (Pk) parasites expressing the Pv Duffy-binding protein region II (PvDBPII) correlate with in vivo protection in the first PvDBPII controlled human malaria infection (CHMI) trials, making the PkGIA an ideal selection tool once the precision of the assay is defined. To determine the precision in percentage of inhibition in GIA (%GIA) and in GIA50 (antibody concentration that gave 50 %GIA), ten GIAs with transgenic Pk parasites were conducted with four different anti-PvDBPII human monoclonal antibodies (mAbs) at concentrations of 0.016 to 2 mg/mL, and three GIAs with eighty anti-PvDBPII human polyclonal antibodies (pAbs) at 10 mg/mL. A significant assay-to-assay variation was observed, and the analysis revealed a standard deviation (SD) of 13.1 in the mAb and 5.94 in the pAb dataset for %GIA, with a LogGIA50 SD of 0.299 (for mAbs). Moreover, the ninety-five percent confidence interval (95 %CI) for %GIA or GIA50 in repeat assays was calculated in this investigation. The error range determined in this study will help researchers to compare PkGIA results from different assays and studies appropriately, thus supporting the development of future blood-stage malaria vaccine candidates, specifically second-generation PvDBPII-based formulations.

Publication status:: Published

Peer review status:: Peer reviewed

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Mertens, J. E., Rigby, C. A., Bardelli, M., Quinkert, D., Hou, M. M., Diouf, A., Silk, S. E., Chitnis, C. E., Minassian, A. M., Moon, R. W., Long, C. A., Draper, S. J., & Miura, K. (2024). Evaluation of the precision of the Plasmodium knowlesi growth inhibition assay for Plasmodium vivax Duffy-binding protein-based malaria vaccine development. Vaccine, 42(16), 3621–3629.

MLA Style

Mertens, J. E., et al. “Evaluation of the Precision of the Plasmodium Knowlesi Growth Inhibition Assay for Plasmodium Vivax Duffy-Binding Protein-Based Malaria Vaccine Development.” Vaccine, vol. 42, no. 16, Elsevier, 2024, pp. 3621–29.

Chicago Style

Mertens, JE, CA Rigby, M Bardelli, D Quinkert, MM Hou, A Diouf, SE Silk, et al. 2024. “Evaluation of the Precision of the Plasmodium Knowlesi Growth Inhibition Assay for Plasmodium Vivax Duffy-Binding Protein-Based Malaria Vaccine Development.” Vaccine 42 (16): 3621–29.
Share
Print